Cyclerion is a leading brand focused on unlocking the full therapeutic potential of the NO-cGMP pathway to address a wide range of serious central nervous system (CNS) diseases. With a dedicated team and a strong determination, Cyclerion strives to bring innovative medicines forward for patients in need. The brand's pipeline is specifically geared towards developing programs for significant CNS diseases.

By exploring the neurophysiology and understanding the crucial role of NO-sGC-cGMP signaling in the CNS, Cyclerion aims to create transformative treatments for patients. Recognized as leaders in drug discovery and development, Cyclerion has an impressive track record of delivering meaningful therapies to patients. The brand's accomplished leadership team contributes to their success by leveraging their expertise and experience.

Founded in 2023, Cyclerion Therapeutics is committed to making a difference in the lives of individuals affected by CNS disorders. With a focus on innovation, the brand continues to advance its scientific research to improve patient outcomes and enhance healthcare